No Data
No Data
Yaohong Pharmaceuticals (688176.SH): has repurchased 1.4651% of the shares accumulated.
On October 8, Gronghui reported that as of September 30, 2024, YAHONG Pharmaceuticals (688176.SH) has cumulatively repurchased 8,351,322 shares, accounting for 1.4651% of the total share capital. The highest price for repurchase transactions is RMB 6.73 per share, the lowest price is RMB 4.99 per share, and the total funds paid amount to RMB 47.787 million (excluding stamp duty, transaction commissions and other transaction costs).
Jiangsu Yahong Meditech Finishes Phase 2 Trial for Muscle-Invasive Bladder Cancer Pre-Treatment Combo
Yahong Medical (688176.SH): The Phase II clinical trial of APL-1202 oral combination with Toripalimab as neoadjuvant treatment for muscle-invasive bladder cancer has been completed and has shown positive efficacy signals.
On September 25th, Alphamab Oncology announced that the Phase II clinical trial of APL-1202 oral combination with toripalimab monoclonal antibody for muscle-invasive bladder cancer (MIBC) neoadjuvant therapy has completed Phase II clinical stage and achieved positive therapeutic efficacy signals. The main objective of this Phase II clinical trial is to evaluate the safety and efficacy of the combination of APL-1202 and toripalimab monoclonal antibody compared to toripalimab monotherapy as neoadjuvant therapy in MIBC subjects. The study population consists of subjects diagnosed with MIBC for the first time and planning to undergo radical cystectomy, who are intolerant or refuse to receive
Need To Know: Analysts Are Much More Bullish On Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) Revenues
Yahong Meditech Says APL1702 Drug's Trial Shows Positive Results; Shares Down 3%
Yahong Pharmaceuticals (688176.SH): The results of the APL-1702 international multicenter phase III clinical trial were selected for the 2024 International Photodynamic and Photodiagnosis Conference.
Yahong Pharmaceuticals (688176.SH) announced that recently, the company's product APL-1702 is used to treat advanced cervical cancer...
No Data
No Data